Enanta Pharmaceuticals stock receives Buy rating from H.C. Wainwright

Investing.com - H.C. Wainwright has assumed coverage on Enanta Pharmaceuticals (NASDAQ:ENTA) with a Buy rating and a $20.00 price target. According to InvestingPro data, analyst targets range from $7 to $24, with the consensus maintaining a Buy recommendation.

The research firm cited a favorable risk-reward profile at current share levels, driven by upcoming clinical catalysts and Enanta’s diversified pipeline in virology and immunology.

H.C. Wainwright highlighted a significant data readout expected in late third quarter 2025, when Phase 2 data of zelicapavir as a therapeutic in high-risk RSV adults is anticipated.

The firm noted Enanta’s strong balance sheet, with approximately $226 million in cash at the end of first quarter 2025 when including the April tax refund.

This cash position exceeds the company’s current market capitalization, which H.C. Wainwright believes creates a favorable risk-reward scenario heading into the RSV Phase 2 data readout.

In other recent news, Enanta Pharmaceuticals announced that the U.S. Food and Drug Administration has approved MAVYRET as the only eight-week treatment for acute hepatitis C virus infection. This expanded indication allows healthcare providers to treat patients immediately upon diagnosis, with clinical trials showing a 96% cure rate. Additionally, Enanta Pharmaceuticals reported its second-quarter fiscal year 2025 results, ending with a cash reserve of $193 million and projecting that its financial resources will sustain operations into fiscal year 2028.

In terms of analyst activity, Citizens JMP raised Enanta Pharmaceuticals’ stock price target to $24 from $23, maintaining a Market Outperform rating. This decision was influenced by the company’s focus on immunology and upcoming Phase 2 results for its oral RSV therapeutic candidate, zelicapavir. However, analysts noted that further development of this candidate will require a partnership. Enanta is also set to present new data from its Phase 2 study of zelicapavir at the 43rd Annual Meeting of the European Society for Paediatric Infectious Diseases in 2025. The presentation will focus on the drug’s effectiveness in reducing viral load in young children with RSV.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.